series-b
Stage
2010
Founded
2
Investors
About
ARTBIO is a clinical-stage radiopharmaceutical company developing a new class of alpha radioligand therapies (ARTs) to treat various cancers, utilizing the alpha-emitting isotope Pb212 for targeted tumor treatment.
Explore ARTBIO's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.